-
Exosomes: Tiny Messengers Revolutionizing Cancer Diagnosis and Therapy(Post)
In the intricate world of cancer biology, a silent conversation is constantly unfolding between tumor cells and their environment. For decades, we viewed this dialogue as a one-way street, with cancer
Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
Cell Death Pathways: Intrinsic vs Extrinsic Apoptosis Guide(Post)At Assay Genie we have created a comprehensive guide outlining everything you need to know about apoptosis! Key Takeaways: Apoptosis is a programmed cell death process, vital for tissue
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting(Post)What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing canc
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
IgG1 Plasma Cells: The Emerging Biomarker for Predicting Cancer Immunotherapy Success(Post)In the relentless fight against cancer, immunotherapy has emerged as a beacon of hope, harnessing the body's own defenses to combat malignant cells. Yet, predicting which patients will respond to the
COVID-19 15分のRAPID POCテスト(Post)COVID-19 15分のRAPID POCテスト 詳細については、hello @ assaygenie.comにお問い合わせください。 概観 Acro Biot
The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.
Unlocking a New Immune Checkpoint: The CD47-Thrombospondin-1 Pathway in Cancer(Post)Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh
Immune-Checkpoint Inhibition in Cancer Prevention(Post)Harnessing Immune-Checkpoint Inhibition for Cancer Prevention Immune-checkpoint inhibition (ICI) has emerged as a pivotal strategy in cancer therapy, particularly in the context of tu
KIR Blockade: Empowering NK Cells for Superior Tumor Clearance(Post)Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec
Mitochondrial Transfer: A Novel Immune Evasion Mechanism in Cancer(Post)In the intricate dance between the immune system and cancer, tumors often deploy cunning strategies to evade destruction. A groundbreaking 2025 study in Nature has unveiled a startling new tactic: can
NK Cell Cytotoxicity Pathway: Receptors, Signalling and Assays(Post)A natural killer cell decides by subtraction. It carries no rearranged antigen receptor and no memory of what it has seen. It presses a panel of germline-encoded receptors against a target and integr
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m
PD-1/PD-L1 Checkpoint Signalling: Pathway, Function and Assays(Post)PD-1 does not switch a T cell off; it moves the threshold. Engagement of PD-1 by PD-L1 recruits a single phosphatase into the immunological synapse, and that one recruitment event is enough to collap
Eosinophils, IL-5 and the Type 2 Granulocyte Axis(Page) Comprehensive Guide to Mononuclear Cells(Post)Immunology · Cell IsolationPeripheral Blood Mononuclear Cells (PBMCs): Composition, Isolation and UseMononuclear cells are the leukocytes with a single, unlobed nucleus — lymphocytes and monocytes. Is
How we can target the underlying immune processes in pathological inflammation in obesity, cancer and liver disease.(Post)Dr. Melissa Conroy, TTMI I am an immunologist and senior research fellow in the Cancer Immunology and Immunotherapy Group, Department of Surgery at Trinity
Tunel 1-Step Assay Kits(Page)TUNEL Assay Kits | 1-Step In Situ Apoptosis Detection | Assay Genie
Binding Is the Easy Part(Post)An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci